
    
      The main purpose of this study is to compare the efficacy, as measured by recurrence-free
      survival (RFS) by blinded independent central review (BICR), of bempegaldesleukin plus
      nivolumab versus nivolumab in patients with completely resected Stage IIIA (lymph node [LN]
      metastasis > 1 mm), Stage IIIB/C/D, or Stage IV (American Joint Committee on Cancer [AJCC]
      8th edition) cutaneous melanoma with no evidence of disease (NED) who are at high risk for
      recurrence.
    
  